Jaguar Health, INC 8-K filings

Jaguar Health successfully passed all five proposals at its 2024 Annual Meeting of Stockholders and anticipates reporting pivotal phase 3 trial results for its cancer supportive care drug crofelemer by July 23, 2024.

Jaguar Health, Inc. issued 393,700 shares of common stock to reduce its royalty debt by $1.5 million.

Jaguar Health has enacted a 1-for-60 reverse stock split and amended its at-the-market offering agreement, removing the previous $75 million limit.

Jaguar Health has announced the successful approval of all proposals at its special shareholder meeting, including the authorization for a reverse stock split, while also receiving an extension to regain Nasdaq compliance.

Jaguar Health has entered into a licensing agreement with Gen Ilac for its drug Crofelemer in Eastern Europe, including a $2 million investment in Jaguar stock at a 75% premium.

Jaguar Health, Inc. issued 10 million common shares in exchange for 40 shares of Series J Preferred Stock in a privately negotiated agreement with Streeterville Capital, LLC.

Jaguar Health, Inc. finalized agreements to extinguish a royalty interest and exchange outstanding warrants for common stock, issuing new preferred and common shares in the process.

Jaguar Health, Inc. has received a delisting notice from Nasdaq after its stock price remained below $0.10 for ten consecutive trading days.